Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 11, Novembre 2011
Page(s) 938 - 940
Section Nouvelles
DOI http://dx.doi.org/10.1051/medsci/20112711008
Publié en ligne 30 novembre 2011
  1. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010 ; 6 : 193–201. [CrossRef] [PubMed]
  2. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 2010 ; 6 : 405–410. [CrossRef] [PubMed]
  3. Britschgi M, Olin CE, Johns HT, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci USA 2009 ; 106 : 12145–12150. [CrossRef]
  4. Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009 ; 65 : 24–31. [CrossRef] [PubMed]
  5. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003 ; 112 : 415–422. [PubMed]
  6. Gilman S, Koler M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 ; 64 : 1553–1562. [CrossRef] [PubMed]
  7. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009 ; 73 : 2061–2070. [CrossRef] [PubMed]
  8. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010 ; 9 : 363–372. [CrossRef] [PubMed]
  9. Ethell DW, Shippy D, Cao C, et al. Aβ-specific T cells reverse cognitive decline and synaptic loss in Alzheimer’s mice. Neurobiol Dis 2006 ; 23 : 351–361. [CrossRef] [PubMed]
  10. Toly-Ndour C, Lui G, Nunes MM, et al. MHC-Independent genetic factors control the magnitude of CD4+T cell responses to amyloid-β peptide in mice through regulatory T-cell mediated inhibition. J Immunol 2011 ; 187 : 4492–4500. [CrossRef] [PubMed]
  11. Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis. J Alzheimer Dis 2010 ; 20 : 1107–1118.
  12. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010 ; 5 : e13950. [CrossRef] [PubMed]
  13. Reddy MM, Wilson R, Wilson J, et al. Identification of candidate IgG biomarkers for Alzheimer’s disease via combinatorial library screening. Cell 2011 ; 144 : 132–142. [CrossRef] [PubMed]